Keywords
tuberculosis
comorbidity
phytotherapy
SWOT analysis
herbal medicines
anti-inflammatory effect
ATC classification
How to Cite
Abstract
The article presents a comprehensive analysis of the pharmacotherapeutic potential and marketing aspects of the use of medicinal products based on Calendula officinalis L. in patients with tuberculosis complicated by comorbid conditions. Particular attention is paid to the clinical feasibility of using calendula herbal preparations as part of palliative and supportive therapy, taking into account frequent lesions of the gastrointestinal tract, hepatobiliary system, mucous membranes, skin, respiratory tract and genitourinary system. Based on the results of the content analysis of registration information and the assortment of the Ukrainian market, the current calendula preparations were systematized by release forms, ATC classification and manufacturers. A SWOT marketing analysis was conducted to determine the strengths and weaknesses, opportunities and threats regarding the presence of this group of herbal remedies on the domestic pharmaceutical market. Regulatory challenges were considered and proposals for their inclusion in state support programs and clinical protocols of supportive treatment were substantiated. The authors emphasize the feasibility of wider use of Calendula officinalis L. in the pharmacotherapy of tuberculosis in order to improve the quality of life of patients and increase the effectiveness of the main treatment.
References
1. Global Tuberculosis Report 2022. World Health Organization. 2022. URL: https://www.who.int/publications/i/item/9789240061729](https://www.who.int/publications/i/item/9789240061729.
2. Weekly report on public health risks. Public Health Center of Ukraine. 2023. URL: https://phc.org.ua/sites/default/files/users/user90/risk_2023_50.pdf
3. Tuberculosis and war: how Ukraine confronts two threats at the same time. Center for Public Health. 07.06.2022. URL: https://phc.org.ua/news/tuberkuloz-i-viyna-yak-ukraina-protistoit-dvom-zagrozam-odnochasno
4. Official statistics of the World Health Organization. Ministry of Health of Ukraine. January 12, 2024. URL: https://moz.gov.ua/article/news/358-ukrainciv-projshli-bezoplatne-likuvannja-likarsko-stijkogo-tuberkulozu-za-novitnoju-shemoju-bpal
5. National regulatory legal acts regulating the system of diagnostics, treatment and prevention of tuberculosis in Ukraine. Ministry of Health of Ukraine. January 12, 2024. URL: https://moz.gov.ua/article/news/verhovna-rada-uhvalila-zakon-pro-podolannja-tuberkulozu-v-ukraini
6. Yurchenko T. Calendula Officinalis L.: Study for Prospects of Creating Combined Dosage Forms with Naturally Similar Properties. SSP Modern Pharmacy and Medicine. 2025. Vol.5. No.1. P.1-25. URL: https://doi.org/10.53933/sspmpm.v5i1.175
7. Osyntseva A. Tuberculosis: Pharmacognosy, Medicinal Plant Raw Materials, Medicinal Plants, Phytotherapy. SSP Modern Pharmacy and Medicine. 2024. Vol. 4 No. 1 Р.1-10. DOI: https://doi.org/10.53933/sspmpm.v4i1.130
8. Shapovalova V. Innovative approaches to medical and pharmaceutical care, pharmacotherapy, and availability of pharmaceutical supplies for Tuberculosis patients in wartime. SSP Modern Pharmacy and Medicine. 2025. Vol.5. No.1. P.1-17. URL: https://doi.org/10.53933/sspmpm.v5i1.170
9. Osyntseva A., Shapovalov V. Management and marketing of circulation of first-line antituberculosis medicines: use of innovative research technologies. SSP Modern Pharmacy and Medicine. 2023. Vol.3. No.4. P.1-13. URL: https://doi.org/10.53933/sspmpm.v3i4.114
10. Osyntseva A. Administration of drugs for pharmacotherapy of Tuberculosis according to GSP requirements. SSP Modern Pharmacy and Medicine. 2024. Vol.4. No.2. P.1-17. URL: https://doi.org/10.53933/sspmpm.v4i2.140
11. Vovk D., Puhach O., Bachynska L. et al. The Role of the general practitioner-family doctor in the pharmacotherapy of Tuberculosis during the war. SSP Modern Pharmacy and Medicine. 2023. Vo.3. No.3. P.1-7. URL: https://doi.org/10.53933/sspmpm.v3i3.102
12. ATC/DDD Index 2024. WHO Collaborating Centre for Drug Statistics Methodology. https://atcddd.fhi.no/atc_ddd_index/
13. Shapovalova V. The ICD-11 for the twenty-first century: the first view from the organizational, legal, clinical and pharmacological aspects. SSP Modern Pharmacy and Medicine. 2022. Vol.2. Nо.1. Р.1–13. URL: https://doi.org/10.53933/sspmpm.v2i1.37
14. Nevzghoda O., Osyntseva A., Shapovalov V. et al. Antitussive codeine medicines in Ukraine: clinical and pharmacological, marketing, regulatory aspects, and forecasts. Annals of Mechnikov’s Institute. 2025. No. 1. P. 33–45. DOI: https://doi.org/10.5281/zenodo.15011812. URL: https://doi.org/10.5281/zenodo.15011812
15. Nevzghoda O., Shapovalov V., Osyntseva A. et al. Codeines Medicine: ABC/VED Analysis, Effectiveness and Rationality of Application. Annals of Mechnikov’s Institute. 2024. No.4. P.29–34. URL: https://doi.org/10.5281/zenodo.14275098
16. Nevzghoda O., Osyntseva A., Shapovalova V. et al. Optimization of pharmacotherapy for chronic pancreatitis: use of ABC/VED analysis in marketing and pharmacoeconomic studies. Proceedings of Shevchenko Scientific Society Medical Sciences. 2025. Vol. 77. Iss. 1. P. 1-14. DOI: https://doi.org/10.25040/ntsh2025.01.16.
17. Nevzghoda O.A., Shapovalov V.V., Shapovalova V.O. et al. Optimisation of antibiotic selection: ABC and VED analysis of medicines against intracellular microorganisms. Tuberculosis, Pulmonary Diseases, HIV-infection. 2025. No. 3 (62). P. 68–79. DOI: http://doi.org/10.30978/TB2025-3-68. URL: http://tubvil.com.ua/article/view/336295
18. Shapovalov V., Shapovalova V., Titarenko I. et al. Quantum medicine and pharmacotherapy of chronic pancreatitis: analysis of drugs and international experience of microwave resonance therapy. Revista Colombiana de Ciencias Químico-Farmacéuticas. 2025. Vol. 54. No. 2. P. 220–244. DOI: https://doi.org/10.15446/rcciquifa.v54n2.117235. URL: https://revistas.unal.edu.co/index.php/rccquifa/article/view/117235
19. Nevzghoda O., Osyntseva A., Shapovalov V. et al. Content analysis of combined anti-tuberculosis drugs. Annals of Mechnikov’s Institute. 2025. No.2. P. 31–38. URL: https://doi.org/10.5281/zenodo.15662640
20. Osyntseva A. The Potential of Vitamin D in Tuberculosis Pharmacotherapy: Retrospective, Marketing Review, and Application Prospects. SSP Modern Pharmacy and Medicine. 2025. Vol. 5. Iss. 1. P. 1–15. DOI: https://doi.org/10.53933/sspmpm.v5i1.172.
22. Yurchenko T. Modern Methods of Standardization of Biologically Active Compounds of Medicinal Plant Raw Materials Calendulae Flos: Chemical Technologies, Analytical Indicators. SSP Modern Pharmacy and Medicine. 2025. Vol.5. No.2. P.1-15. URL: https://doi.org/10.53933/sspmpm.v5i2.183
23. Natchigal A.M., Stringheta A.C.O., Bertoldi M.C. et al. Therapeutic Potential of Calendula officinalis. Pharm Biomed Res. 2018. Vol. 4. Iss. 2. P. 2–15. DOI: https://doi.org/10.18502/pbr.v4i2.214.
24. Rezende A.L.S., Silva C.E., Cruvinel W.M., et al. Drug-Like Properties and Therapeutical Potential of Calendula officinalis L. Progress in Hydrogen Energy. 2024. Vol. 1. P. 301–313. DOI: https://doi.org/10.1016/B978-0-323-95870-3.00014-7.
25. Datta R.W., Waghmare K., Garje S. et al. Exploring the Healing Properties of Calendula officinalis L.: A Comprehensive Overview of Its Therapeutic Potential. Int Res J Mod Eng Tech Sci. 2024. Vol. 6. Iss. 3. P. 3805–3820. DOI: https://doi.org/10.56726/IRJMETS51057.
26. Waghmare K., Datta R.W., Garje S. Comprehensive Review of Pharmacological Activity of Calendula officinalis. IJAERS. 2020. Vol. 7. Iss. 8. P. 45–60. URL: https://ijaers.com/detail/comprehensive-review-of-pharmacological-activity-of-calendula-officinalis/
27. Popovici A., Oancea D. Calendula officinalis – Overview on Applications and Pharmaceutical Uses. Nat Sci Rev. 2024. Vol. 32. P. 10–22. DOI: https://doi.org/10.1093/nsr/nwaa019. URL: https://doi.org/10.1093/nsr/nwaa019
28. PharmaAbides. Pharmacological Activity of Calendula officinalis: A Systematic Review. Pharm. 2023. Vol. 16. Iss. 4. P. 611. DOI: https://doi.org/10.3390/ph16040611.
29. Anonymous. The Science and Tradition of Calendula: A Review of Phytochemistry and Ethnopharmacology. Indian J Pharm Sci. 2024. Vol. 86. Iss. 1. P. 100–115. DOI: https://doi.org/10.36468/pharmaceutical-sciences.121.
30. Efstratiou E., et al. Antimicrobial Activity of Calendula officinalis Petal Extracts. Complement Ther Clin Pract. 2002. Vol. 8. Iss. 2. P. 109–115. DOI: https://doi.org/10.1054/ctcp.2002.0606.
31. Yoshikawa M., et al. Medicinal Flowers III: Hypoglycemic and Gastroprotective Principles from Calendula officinalis. Chem Pharm Bull. 1997. Vol. 45. Iss. 9. P. 1537–1542. DOI: https://doi.org/10.1248/cpb.45.1537.
32. Jimenez Medina E., Garcia Lora A.M. A New Extract of Calendula officinalis Produces Dual In Vitro Effect. BMC Cancer. 2006. Vol. 6. P. 119. DOI: https://doi.org/10.1186/1471-2407-6-119.
33. Machado V.P., et al. Calendula in Modern Medicine: Advancements in Wound Healing and Drug Delivery. Eur J Pharm Sci. 2024. Vol. 183. P. 105712. DOI: https://doi.org/10.1016/j.ejps.2022.105712.
34. Thomas A. Evaluation of Clinical Trials of Herbal Medicines. Clin Phytoscience. 2021. Vol. 7. Iss. 1. P. 12–25. DOI: https://doi.org/10.1186/s40816-021-00293-1.
35. Ilango K. In Vitro Studies to Evaluate the Wound Healing Properties of Calendula. J Ethnopharmacol. 2016. Vol. 189. P. 111–119. DOI: https://doi.org/10.1016/j.jep.2016.05.046.
36. Anonymous. Fifty Year of Global Research in Calendula officinalis L. (1971–2021). Scientometrics. 2022. Vol. 131. P. 123–148. DOI: https://doi.org/10.1007/s11192-021-04221-0.
37. Qaralleh H.A., Mahasneh A.M., Al-Dabbas F. Antibacterial and Antibiofilm Activities of Traditional Herbal Formula. ArXiv. 2021. Preprint. URL: https://arxiv.org/abs/2107.14556
37. Gurel E., Tat M. SWOT Analysis: A Theoretical Review. Journal of International Social Research. 2017. Vol. 10. Iss. 51. P. 994–1006. URL: https://www.sobider.com/Makaleler/895163960_27_G%C3%9CREL%20Ebru.pdf
38. Phadermrod B., Crowder R.M., Wills G.B. Importance–Performance Analysis based SWOT analysis. International Journal of Information Management. 2019. Vol. 44. P. 194–203. DOI: https://doi.org/10.1016/j.ijinfomgt.2016.03.009. URL: https://www.sciencedirect.com/science/article/pii/S0268401216300560
39. Ommani A.R. Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis for Farming System Businesses Management: Case of Wheat Farmers of Shadervan District, Shoushtar Township, Iran. African Journal of Business Management. 2011. Vol. 5. Iss. 22. P. 9448–9454. DOI: https://doi.org/10.5897/AJBM11.1056.
40. Helms M.M., Nixon J. Exploring SWOT analysis – where are we now? A review of academic research from the last decade. Journal of Strategy and Management. 2010. Vol. 3. Iss. 3. P. 215–251. DOI: https://doi.org/10.1108/17554251011064837.
41. Chermack T.J., Kasshanna B.K. The Use and Misuse of SWOT Analysis and Implications for HRD Professionals. Human Resource Development International. 2007. Vol. 10. Iss. 4. P. 383–399. DOI: https://doi.org/10.1080/13678860701718760.
42. IJRAR Staff. Pharmacological Effects of Calendula officinalis. Int J Res Anal Rev. 2023. Vol. 10. Iss. 4. P. 130–140. URL: https://ijrar.org/papers/IJRAR23A2202.pdf
43. European Medicines Agency. Assessment Report on Calendula officinalis L., flos. EMA/HMPC. 2008. Revised 2017. URL: https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-calendula-officinalis-l-flos_en.pdf
44. WHO, CDC. Medicinal Plants: Adjunct Treatment to Tuberculosis Chemotherapy. J Ayurveda Integr Med. 2018. Vol. 9. Iss. 3. P. 211–217. DOI: https://doi.org/10.1016/j.jaim.2018.12.004.
45. Romm A. Calendula – Botanical Medicine for Women’s Health. Botanical Medica. 2010. 2nd ed. P. 213. URL: https://www.botmedwomen.com
46. Verywell Health. What Is Calendula? Verywell Health. 2019. March 7. URL: https://www.verywellhealth.com/what-is-calendula-88312
47. Krippendorff K. Content Analysis: An Introduction to Its Methodology. SAGE Publications. 2018. 4th ed. 472 p. DOI: https://doi.org/10.4135/9781071802878.
48. Elo S., Kyngäs H. The qualitative content analysis process. Journal of Advanced Nursing. 2008. Vol. 62. Iss. 1. P. 107–115. DOI: https://doi.org/10.1111/j.1365-2648.2007.04569.x.
49. Hsieh H.F., Shannon S.E. Three Approaches to Qualitative Content Analysis. Qualitative Health Research. 2005. Vol. 15. Iss. 9. P. 1277–1288. DOI: https://doi.org/10.1177/1049732305276687.
50. Neuendorf K.A. The Content Analysis Guidebook. SAGE Publications. 2017. 2nd ed. 456 p. DOI: https://doi.org/10.4135/9781071802878.n2.
51. Vaismoradi M., Turunen H., Bondas T. Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study. Nursing & Health Sciences. 2013. Vol. 15. Iss. 3. P. 398–405. DOI: https://doi.org/10.1111/nhs.12048.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Alina Osyntseva (Author)